Boston Scientific Invests $1.5 Billion for Stake in MiRus
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 39 minutes ago
0mins
Should l Buy BSX?
Source: Newsfilter
- Strategic Investment: Boston Scientific has invested $1.5 billion to acquire approximately 34% equity in MiRus LLC, aiming to enhance its competitive edge in medical technology through the development of new biomaterials and cardiovascular treatment solutions.
- Exclusive Acquisition Option: The investment agreement includes an exclusive option for Boston Scientific to acquire MiRus's SIEGEL™ Balloon Expandable Transcatheter Aortic Valve Replacement system, which is expected to diversify its product portfolio and increase market appeal.
- Clinical Trial Progress: MiRus has initiated the STAR pivotal trial to evaluate the safety and effectiveness of the SIEGEL valve in 1,025 patients, demonstrating the technology's potential in treating aortic stenosis and possibly improving patient outcomes.
- Future Earnings Outlook: While the investment is expected to have an immaterial impact on Boston Scientific's adjusted earnings per share in 2026, a successful acquisition of MiRus could generate substantial financial returns through future sales revenue.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BSX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BSX
Wall Street analysts forecast BSX stock price to rise
22 Analyst Rating
22 Buy
0 Hold
0 Sell
Strong Buy
Current: 53.550
Low
94.00
Averages
108.14
High
132.00
Current: 53.550
Low
94.00
Averages
108.14
High
132.00
About BSX
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Boston Scientific Invests $1.5 Billion for Stake in MiRus
- Strategic Investment: Boston Scientific has invested $1.5 billion to acquire approximately 34% equity in MiRus LLC, aiming to enhance its competitive edge in medical technology through the development of new biomaterials and cardiovascular treatment solutions.
- Exclusive Acquisition Option: The investment agreement includes an exclusive option for Boston Scientific to acquire MiRus's SIEGEL™ Balloon Expandable Transcatheter Aortic Valve Replacement system, which is expected to diversify its product portfolio and increase market appeal.
- Clinical Trial Progress: MiRus has initiated the STAR pivotal trial to evaluate the safety and effectiveness of the SIEGEL valve in 1,025 patients, demonstrating the technology's potential in treating aortic stenosis and possibly improving patient outcomes.
- Future Earnings Outlook: While the investment is expected to have an immaterial impact on Boston Scientific's adjusted earnings per share in 2026, a successful acquisition of MiRus could generate substantial financial returns through future sales revenue.
See More
Boston Scientific Invests $1.5 Billion for Stake in MiRus and TAVR Option
- Major Investment: Boston Scientific announced a $1.5 billion investment to acquire approximately 34% equity in MiRus LLC, aimed at enhancing its portfolio for treating cardiovascular and orthopedic diseases, particularly the SIEGEL™ Balloon Expandable Transcatheter Aortic Valve Replacement system.
- Exclusive Acquisition Option: The investment agreement includes an exclusive option for Boston Scientific to acquire MiRus's TAVR business for $3 billion upon achieving specific clinical and regulatory milestones, highlighting the company's commitment to innovative medical technologies.
- Technological Advantages: The SIEGEL valve features a unique rhenium alloy design with radial strength superior to cobalt and titanium, and its nickel-free construction and precise placement capabilities may provide physicians with advanced treatment options, potentially improving patient outcomes.
- Clinical Trial Initiation: MiRus has initiated the STAR pivotal trial to evaluate the safety and effectiveness of the SIEGEL valve in 1,025 patients, which is expected to offer a less invasive treatment option for heart disease patients and further enhance market acceptance.
See More
Market Analysis: Stock Performance and Investment Recommendations
- Competitive Pressure Analysis: Boston Scientific's stock has declined due to increased competition, yet analysts suggest holding the stock, indicating confidence in its future potential and reflecting market interest in the medical device sector.
- Cloud and Defense Opportunities: Nokia is seen as a dual beneficiary in cloud computing and defense, with analysts recommending its stock, highlighting its strong performance in technology and defense contracts, which may drive future growth.
- Retail Sector Challenges: Chewy faces challenges in the retail sector, with analysts unable to recommend buying due to the impact of war, reflecting a cautious market attitude towards high-growth retail companies.
- Infrastructure Investment Outlook: Caterpillar is viewed as a beneficiary of growing infrastructure and energy demands, with analysts recommending its stock, demonstrating confidence in its strong demand in construction and energy sectors.
See More
Market Punishes Stocks More Aggressively, Tech Stocks Favored
- Increased Market Punishment: Jim Cramer highlights that the current market punishes companies that miss expectations more severely than in 1999, with Abbott Laboratories down 34% this year, indicating a strong aversion to non-tech stocks.
- Investor Sentiment Divergence: While the S&P 500 and Nasdaq Composite reached record highs, Cramer warns of a pronounced market bifurcation where investors flock to a narrow group of AI winners while aggressively selling off other companies.
- Healthcare Sector Struggles: Cramer notes that companies like Danaher have seen stock declines of 27% due to poor performance, with Boston Scientific and Intuitive Surgical also hitting new lows, reflecting a lack of confidence in the healthcare sector.
- Dot-Com Bubble Comparisons: Cramer cautions against direct comparisons to the dot-com era, arguing that current market dynamics are more extreme, with some hated stocks being excessively punished while loved stocks are excessively favored, creating a stark market polarization.
See More
Market Resembles 1999 but with Greater Punishment for Stocks
- Increased Market Punishment: Cramer highlighted that the current market punishes companies that miss expectations more severely than in 1999, with Abbott Laboratories down 34% this year, indicating investor disappointment in healthcare tech firms.
- Investor Sentiment Divergence: While the S&P 500 and Nasdaq Composite reached record highs, the market has become increasingly bifurcated, with investors flocking to artificial intelligence stocks while aggressively selling off others.
- Healthcare Tech Companies Struggling: Danaher has seen a 27% decline in stock price, and Cramer noted that several medical technology firms, including Boston Scientific and Medtronic, have hit new lows, reflecting a cold market attitude towards non-tech stocks.
- AI Hype and Market Extremes: Cramer cautioned that while investors are overly enthusiastic about AI stocks, the current market dynamics are far more extreme than in 1999, with some hated stocks being excessively punished and loved stocks being excessively favored.
See More
Market Analysis: ASML and Steel Dynamics Performance
- ASML Stock Performance: ASML's stock has been on a continuous rise since its impressive quarterly results, with a $75 increase today, reflecting strong market confidence in its technological leadership despite concerns about a potential pullback.
- Steel Dynamics Recommendation: Steel Dynamics is viewed as an excellent company, with analysts strongly recommending buying its stock, indicating confidence in its future profitability and reflecting the stable demand and growth potential in the steel industry.
- Bloom Energy Investment Opportunity: Bloom Energy is highlighted as a non-combustible power investment choice, with analysts noting a surge in demand from data centers, underscoring its significance and growth potential in the renewable energy market.
- Amphenol Stock Pullback: Amphenol's stock has slightly decreased, which analysts see as a good buying opportunity, demonstrating market confidence in its long-term growth prospects, particularly amid ongoing demand in the connectors and sensors market.
See More
Boston Scientific Invests $1.5 Billion for Stake in MiRus
- Strategic Investment: Boston Scientific has invested $1.5 billion to acquire approximately 34% equity in MiRus LLC, aiming to enhance its competitive edge in medical technology through the development of new biomaterials and cardiovascular treatment solutions.
- Exclusive Acquisition Option: The investment agreement includes an exclusive option for Boston Scientific to acquire MiRus's SIEGEL™ Balloon Expandable Transcatheter Aortic Valve Replacement system, which is expected to diversify its product portfolio and increase market appeal.
- Clinical Trial Progress: MiRus has initiated the STAR pivotal trial to evaluate the safety and effectiveness of the SIEGEL valve in 1,025 patients, demonstrating the technology's potential in treating aortic stenosis and possibly improving patient outcomes.
- Future Earnings Outlook: While the investment is expected to have an immaterial impact on Boston Scientific's adjusted earnings per share in 2026, a successful acquisition of MiRus could generate substantial financial returns through future sales revenue.
See More
Boston Scientific Invests $1.5 Billion for Stake in MiRus and TAVR Option
- Major Investment: Boston Scientific announced a $1.5 billion investment to acquire approximately 34% equity in MiRus LLC, aimed at enhancing its portfolio for treating cardiovascular and orthopedic diseases, particularly the SIEGEL™ Balloon Expandable Transcatheter Aortic Valve Replacement system.
- Exclusive Acquisition Option: The investment agreement includes an exclusive option for Boston Scientific to acquire MiRus's TAVR business for $3 billion upon achieving specific clinical and regulatory milestones, highlighting the company's commitment to innovative medical technologies.
- Technological Advantages: The SIEGEL valve features a unique rhenium alloy design with radial strength superior to cobalt and titanium, and its nickel-free construction and precise placement capabilities may provide physicians with advanced treatment options, potentially improving patient outcomes.
- Clinical Trial Initiation: MiRus has initiated the STAR pivotal trial to evaluate the safety and effectiveness of the SIEGEL valve in 1,025 patients, which is expected to offer a less invasive treatment option for heart disease patients and further enhance market acceptance.
See More
Market Analysis: Stock Performance and Investment Recommendations
- Competitive Pressure Analysis: Boston Scientific's stock has declined due to increased competition, yet analysts suggest holding the stock, indicating confidence in its future potential and reflecting market interest in the medical device sector.
- Cloud and Defense Opportunities: Nokia is seen as a dual beneficiary in cloud computing and defense, with analysts recommending its stock, highlighting its strong performance in technology and defense contracts, which may drive future growth.
- Retail Sector Challenges: Chewy faces challenges in the retail sector, with analysts unable to recommend buying due to the impact of war, reflecting a cautious market attitude towards high-growth retail companies.
- Infrastructure Investment Outlook: Caterpillar is viewed as a beneficiary of growing infrastructure and energy demands, with analysts recommending its stock, demonstrating confidence in its strong demand in construction and energy sectors.
See More
Market Punishes Stocks More Aggressively, Tech Stocks Favored
- Increased Market Punishment: Jim Cramer highlights that the current market punishes companies that miss expectations more severely than in 1999, with Abbott Laboratories down 34% this year, indicating a strong aversion to non-tech stocks.
- Investor Sentiment Divergence: While the S&P 500 and Nasdaq Composite reached record highs, Cramer warns of a pronounced market bifurcation where investors flock to a narrow group of AI winners while aggressively selling off other companies.
- Healthcare Sector Struggles: Cramer notes that companies like Danaher have seen stock declines of 27% due to poor performance, with Boston Scientific and Intuitive Surgical also hitting new lows, reflecting a lack of confidence in the healthcare sector.
- Dot-Com Bubble Comparisons: Cramer cautions against direct comparisons to the dot-com era, arguing that current market dynamics are more extreme, with some hated stocks being excessively punished while loved stocks are excessively favored, creating a stark market polarization.
See More
Market Resembles 1999 but with Greater Punishment for Stocks
- Increased Market Punishment: Cramer highlighted that the current market punishes companies that miss expectations more severely than in 1999, with Abbott Laboratories down 34% this year, indicating investor disappointment in healthcare tech firms.
- Investor Sentiment Divergence: While the S&P 500 and Nasdaq Composite reached record highs, the market has become increasingly bifurcated, with investors flocking to artificial intelligence stocks while aggressively selling off others.
- Healthcare Tech Companies Struggling: Danaher has seen a 27% decline in stock price, and Cramer noted that several medical technology firms, including Boston Scientific and Medtronic, have hit new lows, reflecting a cold market attitude towards non-tech stocks.
- AI Hype and Market Extremes: Cramer cautioned that while investors are overly enthusiastic about AI stocks, the current market dynamics are far more extreme than in 1999, with some hated stocks being excessively punished and loved stocks being excessively favored.
See More
Market Analysis: ASML and Steel Dynamics Performance
- ASML Stock Performance: ASML's stock has been on a continuous rise since its impressive quarterly results, with a $75 increase today, reflecting strong market confidence in its technological leadership despite concerns about a potential pullback.
- Steel Dynamics Recommendation: Steel Dynamics is viewed as an excellent company, with analysts strongly recommending buying its stock, indicating confidence in its future profitability and reflecting the stable demand and growth potential in the steel industry.
- Bloom Energy Investment Opportunity: Bloom Energy is highlighted as a non-combustible power investment choice, with analysts noting a surge in demand from data centers, underscoring its significance and growth potential in the renewable energy market.
- Amphenol Stock Pullback: Amphenol's stock has slightly decreased, which analysts see as a good buying opportunity, demonstrating market confidence in its long-term growth prospects, particularly amid ongoing demand in the connectors and sensors market.
See More
